Myeloproliferative Neoplasms | Specialty

Dr. Mascarenhas on the Impact of Ruxolitinib on the Myelofibrosis Treatment Paradigm

June 5th 2020

John O. Mascarenhas, MD, discusses the impact of ruxolitinib in the myelofibrosis treatment paradigm.

FDA Accepts Application for Ropeginterferon Alfa-2b for Polycythemia Vera

June 5th 2020

The FDA has accepted an application for ropeginterferon alfa-2b for use as a treatment for patients with polycythemia vera.

Dr. Cortes on Future Directions in MPNs

June 3rd 2020

Jorge E. Cortes, MD, discusses challenges with ruxolitinib in myeloproliferative neoplasms.

Hepcidin Mimetic PTG-300 Shows Early Promise in Polycythemia Vera

May 19th 2020

The first-in-class, synthetic hepcidin mimetic agent PTG-300 is being investigated in an ongoing phase 2 clinical trial, with the goal of introducing a novel therapeutic agent to the limited armamentarium in polycythemia vera.

Ruxolitinib Discontinuation in Myelofibrosis Leads to Increased Morbidity Burden, Underscoring Unmet Need

May 18th 2020

John O. Mascarenhas, MD, discusses patient characteristics and outcomes following ruxolitinib discontinuation in myelofibrosis and research efforts being made to address a large unmet need in the space.

Alvocidib Trial Launches in MDS

May 14th 2020

The first patient has been diagnosed with alvocidib, administered in sequence following azacitidine, in the expansion of the phase 1b/2 Zella 102 study in patients with myelodysplastic syndromes.

Dr. Bose on Novel Agents Under Investigation in Myelofibrosis

May 14th 2020

Prithviraj Bose, MD, discusses novel agents under investigation in myelofibrosis.

Research Swells in Myelofibrosis With JAK Inhibitors, Novel Agents

May 13th 2020

Prithviraj Bose, MD, discusses the role of ruxolitinib in myelofibrosis, the potential advantages of next-generation JAK inhibitors, and other novel agents under exploration.

Research Swells in Myelofibrosis With JAK Inhibitors, Novel Agents

May 13th 2020

Prithviraj Bose, MD, discusses the current role of ruxolitinib in myelofibrosis, the potential advantages of next-generation JAK inhibitors, and the novel agents that are being explored as single agents and in combination with ruxolitinib. 

New MDS Subtype Recognized Based on Presence of Common Genetic Variant

May 8th 2020

The International Working Group for the Prognosis of MDS has identified a distinct subtype of myelodysplastic syndromes based on the presence of SF3B1, a nonheritable genetic mutation that causes the disease.

Dr. Michaelis on the Role of Interferon in MPNs

May 4th 2020

Laura C. Michaelis, MD, discusses the role of interferon in myeloproliferative neoplasms.

EU Panel Backs Luspatercept for Anemia in MDS and Beta Thalassemia

May 1st 2020

A European panel has recommended approval of luspatercept for the treatment of anemia in patients with myelodysplastic syndromes and beta thalassemia.

Dr. Bradley on the Utility of Ruxolitinib in Myelofibrosis and Polycythemia Vera

April 28th 2020

Terrence J. Bradley, MD, discusses the utility of ruxolitinib (Jakafi) in myelofibrosis and polycythemia vera.

Dr. Fleur-Lominy on the Current Sequencing Strategy in MPNs

April 28th 2020

Shella Saint Fleur-Lominy, MD, PhD, discusses the current sequencing strategy in the treatment of patients with myeloproliferative neiplasms.

Dr. Nagalla on Efforts to Predict Risk of Thrombosis in Patients With MPNs

April 25th 2020

Dr. Bradley on the Challenges Faced in MPNs

April 25th 2020

Terrence J. Bradley, MD, discusses the challenges of treating patients with myeloproliferative neoplasms.

Dr. Cortes on the Challenges of Using Ruxolitinib in MPNs

April 24th 2020

Jorge E. Cortes, MD, director of the Georgia Cancer Center at Augusta University, discusses the challenges of using ruxolitinib (Jakafi) in patients with myeloproliferative neoplasms (MPNs).

Dr. Snyder on How Ruxolitinib and Fedratinib May Pave the Way to Transplant in Myelofibrosis

April 23rd 2020

David S. Snyder, MD, discusses how ruxolitinib and fedratinib may be used to pave the way toward transplant for patients with myelofibrosis.

Dr. Rossetti on the Utility of JAK Inhibitors in MPNs

April 22nd 2020

James M. Rossetti, DO, discusses the utility of JAK inhibitors in myeloproliferative neoplasms.

Dr. Michaelis on Potential Combination Strategies With Ruxolitinib in Myelofibrosis

April 22nd 2020

Laura C. Michaelis, MD, discusses potential combination strategies with ruxolitinib in myelofibrosis.